Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MC10029 in Relapsed or Refractory BAFFR-Expressing B-Cell Hematologic Malignancies
NCT06191887Phase 1Recruiting
- Sponsor
- Mayo Clinic
- Start
- Mar 2024
- Primary completion
- Dec 2040
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), follicular lymphoma (FL) and 4 more, sponsored by Mayo Clinic. Primary endpoints: Incidence of dose-limiting toxicities at 28 days and Incidence and severity of treatment emergent adverse events at 15 years. Started Mar 2024; status: recruiting.
02
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)follicular lymphoma (FL)mantle cell lymphoma (MCL)marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT06191887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06191887.